Proteonomix, Inc. (PROT)

Market Cap	8.00 -100.0%
Revenue (ttm)	26.00K -27.8%
Net Income	-626.65K
EPS	-0.08
Shares Out	7.91M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,000
Average Volume	29,370
Open	0.000001
Previous Close	n/a
Day's Range	0.000001 - 0.000001
52-Week Range	0.000001 - 0.0001
Beta	-79.17
RSI	43.55
Earnings Date	n/a

About Proteonomix

Proteonomix, Inc., a biotechnology company, focuses on developing therapeutics based upon the use of human cells and their derivatives. The company’s products include Proteoderm, an anti-aging skin cream based on a proprietary and patented matrix of proteins that reduce wrinkles; UMK-121, a treatment for liver disease using a combination of two or three approved drugs to mobilize particular bone marrow stem cells; and StromaCel, a treatment for cardiac patients within two weeks of a myocardial infarction using stem cells derived from donor bone...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1995
• Employees: 2
• Stock Exchange: OTCMKTS
• Ticker Symbol: PROT

Financial Performance

In 2011, Proteonomix's revenue was $26,004, a decrease of -68.79% compared to the previous year's $83,321. Losses were -$1.38 million, -60.12% less than in 2010.